Galantamine Tablet, Film Coated
Product Images NDC 24979-722

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Galantamine (NDC 24979-722). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

12mg-label (12mg Label)

12mg-label (12mg Label)
This document provides details about the medication Gaaniamine hydrobromide (Galantamine) in tablet form, containing Dipense n aih, and presents its dosage information. It notes that the tablets should be stored at room temperature to maintain their efficacy and light-resistance. The manufacturer information and contact details are also given, emphasizing the need to keep the medication out of reach of children.*
FDA Label Image

4mg-label (4mg Label)

FDA Label Image

8mg-label (8mg Label)

FDA Label Image

Chemical Structure (Galantamine 01)

FDA Label Image

Image Description (Galantamine 02)

FDA Label Image

Image Description (Galantamine 04)

FDA Label Image

Image Description (Galantamine 05)

Image Description (Galantamine 05)
This text provides information about the Mean Change From Baseline in ADAS-cog Score after a specified period of treatment with placebo, 24 mg/day, and 32 mg/day. The data is displayed for different weeks of treatment.*
FDA Label Image

Image Description (Galantamine 06)

FDA Label Image

Image Description (Galantamine 07)

Image Description (Galantamine 07)
Percentage of Patients 60 50 40 = 24 = satisfied) E) 2 10 0 Most of Iodily Miroly Wb Mtc Mthy eh hhy o R e e CIBIC-plus Rating*
FDA Label Image

Image Description (Galantamine 08)

Image Description (Galantamine 08)
This is a description of a treatment regimen that lasts for a period of 13 weeks. The text also mentions the location as well, along with some unclear characters and symbols.*
FDA Label Image

Image Description (Galantamine 09)

FDA Label Image

Image Description (Galantamine 10)

FDA Label Image

Image Description (Galantamine 11)

FDA Label Image

Image Description (Galantamine 12)

FDA Label Image

Image Description (Galantamine 13)

FDA Label Image

Figure2 (Galantamine03)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.